Dashboard
Manage Tickers

CRNXCrinetics Pharmaceuticals, ...

Nasdaq crinetics.com


$ 50.98 $ 3.23 (6.78 %)    

Wednesday, 08-May-2024 15:59:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 50.89
$ 50.05
$ 50.84 x 100
$ 0.00 x 0
$ 48.60 - $ 51.29
$ 15.76 - $ 51.29
1,925,827
na
2.74B
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-05-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-07-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-09-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 03-13-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

crinetics-pharmaceuticals-to-present-advancements-from-atumelnant-and-paltusotine-development-programs-at-endo-2024-june-1-4-2024
Crinetics Pharmaceuticals To Present Advan...
05/08/2024 21:44:45

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings fr...

piper-sandler-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-97
Piper Sandler Maintains Overweight on Crin...
05/07/2024 11:08:29

Piper Sandler analyst Yasmeen Rahimi maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the pric...

live-on-cnbc-stempoint-capital-cio-michelle-ross-mentions-crinetics-pharmaceuticals-as-a-glp-1-adjacent-play-during-halftime-segment-opportunities-in-biotech-calling-it-her-best-biotech-idea
Live On CNBC, StemPoint Capital CIO Michel...
04/03/2024 16:40:31

jmp-securities-reiterates-market-outperform-on-crinetics-pharmaceuticals-maintains-80-price-target
JMP Securities Reiterates Market Outperfor...
03/28/2024 14:41:23

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and mai...

oppenheimer-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-55
Oppenheimer Maintains Outperform on Crinet...
03/20/2024 15:52:20

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price...

jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-80
JMP Securities Maintains Market Outperform...
03/20/2024 13:35:41

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and rais...

hc-wainwright--co-maintains-buy-on-crinetics-pharmaceuticals-raises-price-target-to-60
HC Wainwright & Co. Maintains Buy on Crine...
03/20/2024 10:35:16

HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the pri...

jonestrading-maintains-buy-on-crinetics-pharmaceuticals-raises-price-target-to-56
JonesTrading Maintains Buy on Crinetics Ph...
03/20/2024 10:08:30

JonesTrading analyst Lina Kaminski maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target ...

crinetics-pharmaceuticals-inc-files-for-resale-of-up-to-833m-shares-by-the-selling-stockholders
Crinetics Pharmaceuticals Inc Files For Re...
03/19/2024 20:43:13

- SEC Filing

endocrine-disease-focused-crinetics-pharmaceuticals-stock-soars-on-tuesday---heres-why
Endocrine Disease-Focused Crinetics Pharma...
03/19/2024 18:48:34

Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant...

why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Peraso Shares Are Trading Lower By Ove...
03/19/2024 17:48:27

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

hc-wainwright--co-reiterates-buy-on-crinetics-pharmaceuticals-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Crin...
03/19/2024 16:24:54

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $50...

national-cinemedia-reports-upbeat-results-joins-nordstrom-core--main-and-other-big-stocks-moving-higher-on-tuesday
National CineMedia Reports Upbeat Results,...
03/19/2024 14:03:01

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

Core News & Articles
Market-Moving News for March 19th
03/19/2024 12:41:16

CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; S...

crinetics-pharmaceuticals-announced-topline-results-from-pathfndr-2-phase-3-trial-of-paltusotine-for-acromegaly-achieving-the-primary-and-all-secondary-endpoints-nda-submission-to-fda-expected-in-2h-2024
Crinetics Pharmaceuticals Announced Toplin...
03/19/2024 10:06:38

jmp-securities-reiterates-market-outperform-on-crinetics-pharmaceuticals-maintains-60-price-target
JMP Securities Reiterates Market Outperfor...
03/13/2024 15:25:25

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and mai...

oppenheimer-reiterates-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-54
Oppenheimer Reiterates Outperform on Crine...
03/13/2024 12:34:22

Oppenheimer analyst Leland Gershell reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the pric...

hc-wainwright--co-reiterates-buy-on-crinetics-pharmaceuticals-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Crin...
03/13/2024 11:29:12

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $50...

crinetics-announces-positive-topline-results-from-phase-2-trial-of-paltusotine-for-the-treatment-of-carcinoid-syndrome-demonstrated-rapid-and-sustained-reductions-in-frequency-and-severity-of-flushing-episodes-and-bowel-movements
Crinetics Announces Positive Topline Resul...
03/12/2024 20:26:44

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Move...

hc-wainwright--co-maintains-buy-on-crinetics-pharmaceuticals-raises-price-target-to-50
HC Wainwright & Co. Maintains Buy on Crine...
03/08/2024 11:36:47

HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the pri...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION